8-K: Senseonics Reports Strong Revenue Growth in Q4 and Full Year 2023, Eyes 365-Day CGM System Launch

Senseonics Holdings, Inc. announced a 44% increase in fourth-quarter revenue and a 37% increase in full-year revenue for 2023, alongside progress on its 365-day CGM system.

Summary

• Senseonics reported a revenue of $8.0 million for the fourth quarter of 2023, a 44% increase compared to the same period in 2022.
• Full-year 2023 revenue reached $22.4 million, a 37% increase from $16.4 million in 2022.
• The company's gross profit for the fourth quarter was $1.1 million, up from $0.6 million in the prior year.
• For the full year, gross profit was $3.1 million, compared to $2.7 million in 2022.
• Senseonics experienced a net loss of $17.2 million in Q4 2023, compared to a net income of $11.6 million in Q4 2022, primarily due to accounting for embedded derivatives and fair value adjustments.
• The full-year net loss was $60.4 million in 2023, compared to a net income of $142.1 million in 2022, also impacted by accounting adjustments.
• The company expects first-half 2024 global net revenue to be nearly $10 million, representing approximately 16% growth compared to the first half of 2023.
• Senseonics completed the ENHANCE pivotal trial for its 365-day Eversense system and plans to file for FDA approval in the coming weeks.
• They also secured expanded coverage for the Eversense E3 CGM system from UnitedHealthcare and Medicare.

Sentiment

Score: 6

Explanation: The document presents a mixed picture. While revenue growth is strong and there are positive developments with the 365-day system and expanded coverage, the significant net losses and accounting adjustments temper the overall sentiment. The future outlook is positive but uncertain.

Positives

• Senseonics achieved significant revenue growth in both the fourth quarter and full year of 2023.
• The company successfully completed the ENHANCE pivotal trial for its 365-day CGM system.
• Expanded Medicare coverage for the Eversense E3 CGM system increases patient access.
• The appointment of Brian Hansen is expected to accelerate the adoption of Eversense.
• The company strengthened its balance sheet with an additional $10 million loan.
• Gross profit increased year-over-year, indicating improved profitability.

Negatives

• Senseonics reported a net loss of $17.2 million in Q4 2023, a significant decrease from the net income of $11.6 million in Q4 2022.
• The full-year net loss was $60.4 million in 2023, a substantial decrease from the net income of $142.1 million in 2022.
• The net loss was primarily due to accounting for embedded derivatives, fair value adjustments, and the exchange of a portion of the 2025 notes.
• Research and development expenses increased by $9.0 million year-over-year for the full year 2023.

Risks

• The company faces uncertainties in the execution of Ascensia's independent business unit for the commercialization of Eversense.
• There are uncertainties in insurer, regulatory, and administrative processes and decisions.
• The development and registration of new technology carries inherent uncertainties.
• The current economic environment could impact the company's performance.
• The company's future performance is subject to various risk factors detailed in their SEC filings.

Future Outlook

Senseonics expects first-half 2024 global net revenue to be nearly $10 million, representing approximately 16% growth compared to the first half of 2023, and anticipates the commercial launch of the 365-day product in Q4. They plan to provide full-year 2024 guidance in the second quarter.

Management Comments

• Tim Goodnow, PhD, President and Chief Executive Officer of Senseonics, stated that 2023 was a successful year across the business.
• He highlighted the completion of the ENHANCE clinical trial, expanded coverage, and a strengthened balance sheet.
• He expressed excitement about Brian Hansen's appointment and the potential for accelerated adoption of Eversense.
• Management believes the robust product innovation cycle will offer substantial benefits to diabetes patients and position Senseonics for its next phase of growth.

Industry Context

This announcement comes as the CGM market continues to grow, with increasing demand for long-term implantable solutions. Senseonics is positioning itself to compete with other CGM providers by focusing on longer-lasting sensor technology and expanded insurance coverage.

Comparison to Industry Standards

• Senseonics' 37% revenue growth for the full year 2023 is strong compared to some competitors in the medical device space, but it is important to note that the company is still in a growth phase and not yet profitable.
• Dexcom, a major competitor in the CGM market, reported a 24% revenue growth in 2023, indicating that Senseonics is growing at a faster rate, but from a smaller base.
• Abbott, another key player, has a broader portfolio of medical devices, making a direct comparison difficult, but their diabetes care division also shows strong growth.
• The successful completion of the ENHANCE trial and the imminent FDA submission for the 365-day system are critical milestones for Senseonics, as longer-lasting sensors are a key differentiator in the market.
• The expansion of Medicare coverage is a positive development, as it increases the addressable market for Senseonics' products, similar to how other companies have benefited from favorable reimbursement policies.

Management Changes

Stakeholder Impact

• Shareholders may be concerned about the net losses but encouraged by the revenue growth and product development progress.
• Employees may be impacted by the company's financial performance and strategic shifts.
• Customers (patients) will benefit from the potential launch of the 365-day system and expanded access to the Eversense E3 CGM.
• Suppliers may see increased demand as the company expands its operations.
• Creditors may be monitoring the company's debt levels and financial performance.

Next Steps

• Senseonics plans to file for FDA approval of the 365-day Eversense system in the coming weeks.
• The company anticipates the commercial launch of the 365-day product in Q4.
• Senseonics plans to provide its full-year 2024 financial outlook in the second quarter.
• The company will continue to focus on the commercialization of the Eversense E3 CGM system.

Key Dates

Keywords

Senseonics, CGM, Eversense, Glucose Monitoring, Diabetes, Medical Technology, FDA Approval, Revenue Growth, Financial Results, Implantable Sensor